Positioning asset to become an 18-hour activity hub that better serves the lifestyle needs of the surrounding community Meets neighborhood demand for an upscale coffeehouse, premium fitness concepts and executive suites by bringing in Starbucks Reserve, Pvolve, RVE Fitness and CUBExec HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR), a neighborhood-focused owner and operator of open-air shopping centers in Texas and Arizona, today announced that it has commenced a strategic transformation of the merchandising mix at Davenport Village (“Davenport”) in Austin, Texas that is expected to re-energize the center and strengthen its competitive position within the upscale neighborhoods it serves: Davenport Ranch, Westlake, Rob Roy and Barton Creek. Whitestone is creating a vibrant, 18-hour activity hub that more appropriately...

VANCOUVER, British Columbia, March 10, 2025 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) announces that it has filed notice of a meeting of shareholders, a management information circular, and related documents (collectively, the “Meeting Materials”) to convene a special meeting (the “Meeting”) of shareholders. The Meeting will take place on March 31, 2025 at 10:00 AM (Vancouver Time). Copies of the Meeting Materials are available for review under the profile for the Company on SEDAR+ (www.sedarplus.ca) and on Anfield’s corporate website (https://anfieldenergy.com). The Meeting has been convened to seek shareholder approval for a consolidation (the “Consolidation”) of the Company’s common shares (“Shares”) on the basis of one new Share for up to 200 currently issued...

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. The REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial. After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose. When evaluating the...

SINGAPORE and SHANGHAI, March 10, 2025 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, “we” or “our”) a key player in the global hotel industry, today announced that it will schedule to release its unaudited financial results for the fourth quarter and full year of 2024 on Thursday, March 20, 2025 (Hong Kong time), after the trading hours of The Stock Exchange of Hong Kong Limited and before the opening of the U.S. market. H World’s management will host a conference call at 8 a.m. (U.S. Eastern time) on Thursday, March 20, 2025 (or 8 p.m. (Hong Kong time) on Thursday, March 20, 2025) following the announcement. To join by phone, all participants must pre-register this conference call using the Participant Registration link of https://register-conf.media-server.com/register/BI303638c962504ffcb81bb09e374f8485....

Five presentations affirm positive outcomes utilizing inhaled insulin An sNDA filing for Afrezza in pediatric population anticipated in 2025DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 10, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase data from recent studies of inhaled insulin across five presentations at the 18th International Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam. “Data from both the INHALE-1 pediatric and INHALE-3 adult studies continue to drive groundbreaking conversations around inhaled insulin,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area...

SYN461x is optimized for power, system integration, size, and time to market with outstanding rate-over-range and seamless interoperability to target an ~$3.2 billion market opportunity NUREMBERG, Germany, March 10, 2025 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) has extended its award-winning Veros™ Triple Combo connectivity portfolio with the SYN461x family of ultra-low-power (ULP) Wi-Fi® 2.4/5/6 GHz, Bluetooth® 6.0 and Bluetooth Low Energy (BLE), and IEEE 802.15.4 (Zigbee®/Thread®) systems on chip (SoCs). Designed for the embedded Edge AI Internet of Things (IoT), the SYN461x is optimized for power, system integration, size, and rapid time to market while delivering Veros’ characteristic outstanding rate-over-range performance and seamless interoperability. The versatile Matter-compliant SoCs offer advanced...

Featuring three power levels, the SR-Series MCUs scale Astra AI-Native hardware and open-source software to accelerate the development of low-power, cognitive IoT devices NUREMBERG, Germany, March 10, 2025 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) has extended its award-winning Synaptics AstraTM AI-Native platform with the SR-Series high-performance adaptive microcontroller units (MCUs) for scalable context-aware Edge AI. The series features three tiers of operation: performance (100 GOPS), efficiency, and ultra-low-power (ULP) always-on (AON) to deliver intelligence at every power level. Based on an Arm® Cortex®-M55 core and the Arm Ethos™-U55 neural processing unit (NPU), the SR-Series is supported by the AstraTM Machina Micro development kit and open-source SDK. It is optimized for multimodal consumer,...

To Nasdaq Copenhagen A/S                        10th March 2025                                        Announcement no. 22/2025 Final terms for bonds to be listed 11th March 2025 On 11th March 2025, Jyske Realkredit A/S will be listing new Covered Bonds (SDO). Final terms for the bonds are attached to this announcement. The full prospectus for the Bonds consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated June 28th, 2024. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely,Jyske Realkredit A/S www.jyskerealkredit.com Please observe...

Government Debt Management announces the following change to its annual Prospect for 2025. The current plan is to issue a new inflation-indexed bond series maturing in 2044, with plans for market making. Instead, an inflation-indexed bond maturing in 2050 with planned market making will be issued this year.

Correction – All attachments replacedBecause of pagination faults, all attachments to the release, in English and Icelandic, have been replaced. —— Orkuveitan has published its consolidated financial statements for the year 2024, presenting highly positive results. The Group’s profit increased by 45% from 2023, amounting to ISK 9.3 billion. A dividend proposal of ISK 6.5 billion has been put forth. The Group comprises the parent company, Veitur, Orka náttúrunnar, Ljósleiðarinn, and Carbfix. Its shareholders are the City of Reykjavík, the Municipality of Akranes, and the Municipality of Borgarbyggð. “The excellent operating results last year provide a strong foundation for Orkuveitan’s new phase of growth,” says CEO Sævar Freyr Þráinsson. “We have met significant demand for our services and will continue to invest responsibly...